Gilead, Bristol-Myers Say Direct Buyers Antitrust Suit Too Late
Gilead Sciences and Bristol-Myers Squibb urged a California federal judge Thursday to nix direct buyers' claims alleging the pharmaceutical companies engaged in anti-competitive conduct to block generic competition and keep HIV...To view the full article, register now.
Already a subscriber? Click here to view full article